AGA Updates Clinical Guidance for Obesity and Weight Management Treatment Options
By
Marilynn Larkin
Summary
The American Gastroenterological Association (AGA) has updated its POWER (Practice Guide on Obesity and Weight Management, Education, and Resources) framework to help clinicians navigate the expanding landscape of obesity treatment options. The update reflects the emergence of new obesity medications (OMs) and positions gastroenterologists and hepatologists as key players in personalized obesity management approaches.
Source
Twitter / XAGA Updates Clinical Guidance for Obesity and Weight Management Treatment Optionsmdsc.peKey quotes
· 3 pulledUpdated guidance from the American Gastroenterological Association (AGA) will help clinicians navigate the growing number of weight management options.
This update to the AGA's landmark POWER framework reflects changes in the obesity care landscape, particularly with the advent of new obesity medications (OMs) and expanded treatment options.
It positions gastroenterologists and hepatologists as key players in a more personalized approach to obesity management.
You might also wanna read
National Psoriasis Foundation Review Examines GLP-1 Receptor Agonists for Psoriasis with Metabolic Comorbidities
This review from the US National Psoriasis Foundation Medical Board provides an evidence-informed narrative synthesis on GLP-1 receptor agon
doi.org·27d ago
GLP-1 Prescriptions Rise as U.S. Obesity Rates Show Modest Decline, New Data Indicates
New data from EPIC Research shows that GLP-1 medications like Ozempic and Wegovy are having a population-wide impact on obesity rates. As pr
gizmodo.com·25d ago
Study: GLP-1 Weight Loss Drugs Linked to Decline in Daily Physical Activity
A new study analyzing NIH All of Us Research Program data, including Fitbit activity records and electronic health records, reveals that adu
neurosciencenews.com·9d ago
Semaglutide Shows Chondroprotective Effects in Osteoarthritis Through Weight Loss-Independent Metabolic Mechanism
This research article demonstrates that semaglutide, a GLP-1 receptor agonist, provides chondroprotective effects in osteoarthritis mouse mo
GLP-1 Therapy Reduces Migraine Frequency by More Than Half in Obesity Patients
A study from the University of Naples found that liraglutide, a GLP-1 receptor agonist typically used for diabetes and obesity, significantl
medlink.com·6mo ago
Edmonton hospital offers non-surgical weight loss procedure using endoscopic stitching
A new non-surgical weight loss procedure called endoscopic sleeve gastroplasty (ESG) is being performed at Edmonton's Royal Alexandra Hospit
cbc.ca·25d agoComments
Sign in to join the conversation.
No comments yet. Be the first.